Chinese expert consensus statement on the clinical application of <scp>AFP</scp>/<scp>AFP‐L3</scp>%/<scp>DCP</scp> using <scp>GALAD</scp> and <scp>GALAD</scp>‐like algorithm in <scp>HCC</scp>
Chenjun Huang, Xiao Xiao, Lin Zhou, Fuxiang Chen, Jianyi Wang, Xiaobo Hu, Chunfang Gao
Abstract
BACKGROUND: Primary hepatocellular carcinoma (HCC) is one of the most prevalent world-wide malignancies. Half of the newly developed HCC occurs in China. Optimizing the strategies for high-risk surveillance and early diagnosis are pivotal for improving 5-year survival. Constructing the scientific non-invasive detection technologies feasible for medical and healthcare institutions is among the key routes for elevating the efficacies of HCC identification and follow-up. RESULTS: Based on the Chinese and international guidelines, expert consensus statements, literatures and evidence-based clinical practice experiences, this consensus statement puts forward the clinical implications, application subjects, detection techniques and results interpretations of the triple-biomarker (AFP, AFP-L3%, DCP) based GALAD, GALAD like models for liver cancer. CONCLUSIONS: The compile of this consensus statement aims to address and push the reasonable application of the triple-biomarker (AFP, AFP-L3%, DCP) detections thus to maximize the clinical benefits and help improving the high risk surveillance, early diagnosis and prognosis of HCC.